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The Rockefeller University presents
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Mycolic Acids of
Mycobacterium tuberculosis:
An Achilles Heel or a Neutralizing Weapon?
William R. Jacobs Jr., Ph.D.
Professor, Albert Einstein College of Medicine
Investigator, Howard Hughes Medical Institute

Visit
our
Web site:
www.
rockefeller.
edu/
lectures.
html

Date:9

Friday, January 19, 2001

T i m e: e

3:15 p.m. Tea
3:45 p.m. Lecture

Place:

Caspary Auditorium
The Rockefeller University
East 66th Street and York Avenue
New York City

Mycobacterium tuberculosis, the tubercule bacillus, was originally described by Robert Koch and, characterized by its unusual staining properties, proven to be the causative agent of tuberculosis (TB).These
acid-fast staining properties have been found to result from the unique lipid surface that is predominantly long-chain fatty acids called mycolic acids.These mycolic acids are common to the entire genus
of Mycobacterium, thus providing a unique signature for the species.The TB-specific drugs isoniazid and
ethionamide have been shown to target the synthesis of these mycolic acids. Using a combination of
genetic, biochemical and X-ray crystallographic analyses, the target, InhA, has been identified and
characterized. Specific inhibition of InhA induces the lysis of mycobacterial cells, thus defining a key
Achilles heel for the mycobacterial species that has led to novel drug development.
Both M. tuberculosis and M. leprae, the causative agent of leprosy, have been shown to decorate their
mycolic acids with unique cyclopropyl groups. Mutations that affect cyclopropanations of mycolic
acids have been shown to render M. tuberculosis unable both to cord and to cause a persistent infection
in mice.The cyclopropanated lipids appear to represent a unique virulence factor that protects pathogenic mycobacteria against an effective immune response.Thus, mycolic acids represent a unique
two-edged sword for M. tuberculosis pathogenesis.
William R. Jacobs Jr., Ph.D., began studying M. tuberculosis while a postdoctoral fellow with Barry
Bloom, Ph.D., at Albert Einstein College of Medicine, where he sought to develop BCG as a recombinant vector for eliciting immune responses against cloned foreign antigens. Drs. Jacob and Bloom were
the first to introduce foreign DNA into slow-growing mycobacteria using a novel recombinant DNA
vector called a shuttle plasmid.This system further allowed Dr. Jacobs to achieve the first transformation
of BCG and M. tuberculosis. Drs. Jacobs and Bloom went on to develop the first recombinant BCG
vaccines and demonstrated that they could elicit protective immune responses to a variety of cloned
foreign antigens. Dr. Jacobs has used phage systems to develop a variety of tools for genetically
manipulating mycobacteria including transposon delivery phages, luciferase reporter phages and
specialized transducing phages.
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